tradingkey.logo

Myriad Genetics Inc

MYGN
View Detailed Chart

3.890USD

-0.140-3.47%
Close 05/09, 16:00ETQuotes delayed by 15 min
358.66MMarket Cap
LossP/E TTM

Myriad Genetics Inc

3.890

-0.140-3.47%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.47%

5 Days

-48.54%

1 Month

-53.96%

6 Months

0.00%

Year to Date

0.00%

1 Year

0.00%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 17 analysts
HOLD
Current Rating
9.750
Target Price
150.64%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

112
Total
7
Median
9
Average
Company name
Ratings
Analysts
Myriad Genetics Inc
MYGN
17
Medtronic PLC
MDT
34
Stryker Corp
SYK
33
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
28
Dexcom Inc
DXCM
27
1
2
3
...
23

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(3)
Neutral(0)
Buy(0)
Indicators
Sell(0)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
--
--
RSI(14)
--
--
STOCH(KDJ)(9,3,3)
--
--
ATR(14)
--
--
CCI(14)
--
--
Williams %R
--
--
TRIX(12,20)
--
--
StochRSI(14)
--
--
Moving Average
Sell(3)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
--
--
MA10
--
--
MA20
--
--
MA50
--
--
MA100
--
--
MA200
--
--

News

More news coming soon, stay tuned...

Company

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Company codeMYGN
CompanyMyriad Genetics Inc
CEOMr. Samraat S. (Sam) Raha
Websitehttps://myriad.com/